您的位置:万维书刊网 >>sci/scie期刊 >>医药卫生1>>内分泌学与代谢

Acta Diabetologica(研究方向:内分泌学与代谢) (官网投稿)

  • 期刊简称
  • 参考译名
  • 核心类别 SCI期刊(2018), SCIE期刊(2018), 外文期刊,
  • IF影响因子
  • 自引率
  • 主要研究方向



Acta Diabetologica(双月刊),创刊于1991年,出版国家为意大利。Acta Diabetologica是一本杂志,发表关于糖尿病和相关代谢疾病的实验和临床研究的报告。欢迎对糖尿病和代谢疾病研究的生化,生理,病理生理和临床方面的原始贡献。报告以原始文章,短信和信件的形式出版给编辑。邀请的评论和社论也发表。还提供了一种方法学论坛,其中发表了关于体内和体外糖尿病方法学方面的贡献。总编辑很高兴地考虑在糖尿病...[显示全部]







4、信息说明:本刊信息来源于网络,包括 SCI 收录核心期刊,增补期刊,期刊收录数据每年进行更新。本站是公益性网站,为网友投稿提供免费服务,由于受相关约束,我们不能提供相关期刊的影响因子、JCR期刊分区等数据供大家参考,造成不便,敬请谅解。




Author Guidelines


Aims and Scope



Acta Diabetologica is a journal that publishes reports of experimental and clinical research on diabetes mellitus and related metabolic diseases. Original contributions on biochemical, physiological, pathophysiological and clinical aspects of research on diabetes and metabolic diseases are welcome. Reports are published in the form of original articles, short communications and letters to the editor. Invited reviews and editorials are also published. A Methodology forum, which publishes contributions on methodological aspects of diabetes in vivo and in vitro, is also available. The Editor-in-chief will be pleased to consider articles describing new techniques (e.g., new transplantation methods, metabolic models), of innovative importance in the field of diabetes/metabolism. Finally, workshop reports are also welcome in Acta Diabetologica.


Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.


Reports of animal experiments must state that the "Principles of laboratory animal care" (NIH publication No.  86-23, revised 1985) were followed, as well as specific national laws (e.g. the current version of the German Law on the Protection of Animals) where applicable.


The Editor-in-chief reserves the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfil the above-mentioned requirements.


The journal is open for publication of supplements and for publishing abstracts of scientific meetings. Condition can be obtained from the Editor-in Chief or the publisher.


Types of papers

It is the policy of Acta Diabetologica to ensure balance, independence, objectivity and scientific rigor in the journal. All authors are expected to disclose to the readers any real or apparent conflict of interest that may have a direct bearing on the subject matter of the article. It is mandatory for any type of paper to publish a conflict statement in the article itself, and to submit the conflict disclosure form in addition (you can find the form on the journal’s homepage on springer.com).


are usually written by members of the Editorial and Advisory Board. They should not exceed 500 words, not include more than 1 illustration and references should be limited to 5.


Reviews are usually invited, although unsolicited reviews may be considered for publication. Authors hoping to submit an unsolicited review should first consult the Editors-in-Chief at patrizia.bianchi@springer.com

Proposals should include an abstract or detailed summary and a full outline of the review, along with a full author list with titles, affiliations and areas of expertise.

Review Articles are subject to the peer review process. Text length must not exceed 4,000 words. The number of references should not exceed 70 . Up to 15 figures are allowed. The abstract does not need to be structured.

Clinical Trials, Systematic Reviews and Meta-Analyses

Acta Diabetologica supports initiatives to improve the performance and reporting of trials, part of which includes prospective registering and numbering of clinical trials. The International Committee of Medical Journal Editors (ICMJE) has implemented the World Health Organisation (WHO) definition of clinical trials which states that a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. This definition includes phase I to Phase IV trials.

All clinical trials submitted to Acta Diabetologica must be registered with an approved ICMJE clinical trial registry (such as clinicaltrials.gov); Acta Diabetologica accepts registration of clinical trials in any of the primary registries that participate in the World Health Organization International Clinical Trial Registry Platform. Authors must include the unique clinical trial number and the name of the registry on the manuscript’s title page.

Authors of reports on randomized controlled trials (RCTs) are required to complete the checklist outlined in the Consolidated Standards of Reporting Trials (CONSORT) Statement. The instructions and checklist are designed to ensure that information pertinent to the trial is included in the study report. Acta Diabetologica requires that the CONSORT checklist is submitted with RCT manuscripts; CONSORT information may be posted with accepted manuscripts as online-only supplementary materials at the request of the editors or the authors.

Authors of reports on systematic reviews and meta-analyses are required to complete the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The PRISMA Statement consists of a 27-item checklist and a four-phase flow diagram that have been developed to help authors improve the reporting of systematic reviews and meta-analyses. Acta Diabetologica requires that the completed checklist and diagram are submitted with systematic reviews and meta-analyses; PRISMA information may be posted with accepted manuscripts as online-only supplementary materials at the request of the editors or the authors.

Original papers

should have a structured abstract (Aims, Methods, Results and Conclusions), must not exceed 3,000 words and should not include more than 6 illustrations and tables. Each separate part of a figure (a, b, etc.) counts as an illustration. Up to 45 references are permitted..

Case reports

They must not exceed 2,000 words, 5 references and 5 authors. They should not have an abstract, not include more than 2 illustrations.

Short communications

They must not exceed 1,000 words, should not have an abstract. They should not exceed 1,000 words; 2 illustrations and up to 5 references are permitted.

Letters to the editors

must not exceed 600 words (and 5 references) with one table or figure and without abstracts. They should be addressed to the Editors-in-Chief. Submitted letters will be subject to shortening and editorial revision.

The submission of manuscripts is via Editorial Manager. Please use the following


Manuscript Submission

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.


Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission

Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen.




M Porta,都灵(意大利)




M Federici,罗马(意大利)

A Secchi,米兰(意大利)




R Bonadonna,帕尔马(意大利)


P Marchetti,比萨(意大利)

U Pagotto,博洛尼亚(意大利)

G Pugliese,罗马(意大利)

帕萨多(意大利)G Sartore




G Pozza,米兰(意大利)








KGMM Alberti,伦敦(英国)



PY Benhamou,格勒诺布尔(法国)

GB Bolli,佩鲁贾(意大利)



L Byung-Wan,首尔(大韩民国)

M Cardellini,罗马(意大利)

G CharpentierCorbeil Essonnes(法国)

G Chiumello,米兰(意大利)




D Cucinotta,墨西拿(意大利)

L Czupryniak,华沙(波兰)

RA DeFronzo,圣安东尼奥(美国)



F Dotta,锡耶纳(意大利)

ME Dumas,伦敦(英国)



波士顿(美国)P Fiorina

PR FlattColeraine(英国)

F Folli,圣安东尼奥(美国)

CM Forsblom,赫尔辛基(芬兰)

波拉尼亚(意大利)G Forlani

A FritscheTübingen(德国)

投稿问答最小化  关闭